Insider · CIK 0001903865
Samina Khan
Files at RETA (REATA PHARMACEUTICALS INC). First filing Mar 6, 2023, latest Mar 8, 2023.
In brief
Samina Khan files SEC Form 4 as officer at RETA (REATA PHARMACEUTICALS INC). Since Mar 6, 2023, Samina Khan has reported 0 open-market buys worth $0 and 2 open-market sells worth $2.7M, the latest filed on Mar 8, 2023.
A track record needs three past buys with six months of prices behind them; Samina Khan has 0, so none is measured yet.
The newest scored trade: sold $331k of RETA on Mar 7, 2023, filed Mar 8, 2023, scored 45 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | REATA PHARMACEUTICALS INC | $331k 3,961 shares | -9% | - | |
| 50Moderate | REATA PHARMACEUTICALS INC | $2.4M 27,813 shares | -39% | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 7, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -3,961 | $83.46 | $331k | 40,131 | Mar 8, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | MOption exercise Class A common stock | +25,000 | $27.32 | $683k | 71,905 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -3,395 | $83.70 | $284k | 68,510 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -18,956 | $85.02 | $1.6M | 49,554 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -2,649 | $85.38 | $226k | 46,905 | Mar 6, 2023 |
| Mar 3, 2023 | RETA REATA PHARMACEUTICALS INC | SOpen-market sale Class A common stock | -2,813 | $87.36 | $246k | 44,092 | Mar 6, 2023 |
| Mar 2, 2023 | RETA REATA PHARMACEUTICALS INC | MOption exercise Employee Stock Option (right to buy)derivative | -25,000 | $0.00 | $0 | 25,000 | Mar 6, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Class A common stock | +11,756 | $0.00 | $0 | 46,905 | Jan 4, 2023 |
| Jan 3, 2023 | RETA REATA PHARMACEUTICALS INC | AGrant or award Employee Stock Option (right-to-buy)derivative | +47,738 | $0.00 | $0 | 47,738 | Jan 4, 2023 |
Questions about Samina Khan
Answered from the filings on this page, as of the latest one.
Is Samina Khan buying or selling?
Not in the last 12 months. Samina Khan's latest open-market trade on SEC Form 4 was sold $331k of RETA on Mar 7, 2023.
How did Samina Khan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Samina Khan has 0.
Where does Samina Khan file Form 4?
Samina Khan has filed Form 4 at RETA (REATA PHARMACEUTICALS INC) as SVP, Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.